Access to voluntary family planning and reproductive health (FP/RH) services is vital for safe motherhood and healthy families. Having a choice of modern contraceptives allows couples to plan and space births, ensuring families have the means to properly care for their children. USAID ensures an uninterrupted supply of quality FP/RH commodities worldwide through the USAID Global Health Supply Chain Program—Procurement and Supply Management (GHSC-PSM) project.1

With a population of nearly 35 million2—almost triple what it was in 1990—the average woman in Angola gives birth to 5.4 children in her lifetime.3 In 2022, approximately 36.4 percent of married Angolan women had an unmet need for FP—meaning they wanted to avoid pregnancy but were not using a modern method of birth control.4

The maternal mortality ratio in Angola is 241 per 100,000 live births, compared to 542 for sub-Saharan Africa, on average.5 The child mortality rate is 71 deaths among children under 5 per 1,000 live births, compared to 74 for the sub-Saharan region.6

To address Angola’s maternal and child health needs, the Government of Angola is collaborating with USAID and other partners. This includes increasing investment in FP/RH to reach a projected modern contraceptive prevalence rate of 16.3 percent among married women aged 15 to 49 by 2022.7

---

1 Unless otherwise noted, all figures reported in this brief are over the life of the GHSC-PSM project and do not reflect USAID’s contraceptive investment prior to FY 2017. The figures reflect delivered commodities, not shipped commodities, and may not be comparable to figures reported in previous materials.


USAID Contraceptive Investment

In partnership with the Government of Angola and other in-country stakeholders, USAID has supported the procurement and distribution of over 5.8 million FP/RH products to USAID-supported facilities and organizations in Angola from FY 2017-2022. The contraceptives, when combined with proper counseling and correct use, are estimated to provide approximately 1 million couple years protection and to help prevent:

- 410,000 unintended pregnancies
- 1,000 maternal deaths
- 136,000 abortions
- 10,000 child deaths

These investments in contraceptives have the potential of saving approximately $17 million in direct spending on healthcare—resources that can be reinvested in Angola’s health system.

Through its investments in contraceptives and supply chains, USAID, in collaboration with other global and in-country partners, is helping Angola meet its people’s FP/RH needs. Countries that partner with USAID to invest in FP/RH can achieve greater self-reliance by improving their overall health systems and empowering families to plan for their futures.

Methodology

To measure the impact of FP/RH programs, the indicators presented in this brief were calculated using the Impact 2 model, a socio-demographic mathematical model, using procurement data from the GHSC-PSM project database.

The FP/RH impact indicators, as reported in this brief, estimate the demographic, health, and economic impact of USAID’s support of contraceptives to Angola’s health programs.

For more information, please contact PSMMonitoringandEval@ghsc-psm.org.

CONTACT US

John Vivalo
USAID Bureau of Global Health, Office of Population and Reproductive Health, Commodities Security and Logistics Division
Tel: +1 202-916-2165

Alan Bornbusch
USAID Bureau of Global Health, Office of Population and Reproductive Health, Commodities Security and Logistics Division
Tel: +1 202-916-2159

A health worker measures the height of a family planning patient prior to her appointment. Photo credit: GHSC-PSM

“Thanks to family planning I can accompany my daughter’s growth and provide her with better living conditions.”

—Linda, woman of child-bearing age in Maternal and Child Center in the municipality of Saurimo, Angola

<table>
<thead>
<tr>
<th>CONTRACEPTIVE METHODS</th>
<th>TOTAL PRODUCTS DELIVERED FY 2017-2022*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined oral contraceptives</td>
<td>3.1M</td>
</tr>
<tr>
<td>Copper bearing intrauterine devices</td>
<td>35K</td>
</tr>
<tr>
<td>Implantable contraceptives</td>
<td>54K</td>
</tr>
<tr>
<td>Injectable contraceptives</td>
<td>1.6M</td>
</tr>
<tr>
<td>Progestin only pills</td>
<td>1M</td>
</tr>
<tr>
<td>TOTAL NUMBER OF CONTRACEPTIVES DELIVERED</td>
<td>5.8 M</td>
</tr>
<tr>
<td>TOTAL VALUE OF COMMODITIES</td>
<td>$2.8 M*</td>
</tr>
</tbody>
</table>

*This figure represents solely the calculation of the value of commodities and does not include shipment or other associated costs.